Science | Nature | Cell | View More
Natural Products
Quetiapine fumarate
ChemFaces products have been cited in many studies from excellent and top scientific journals
Product Name Quetiapine fumarate
Price:
CAS No.: 111974-72-2
Catalog No.: CFN98513
Molecular Formula: (C2H21N25O3S).C2H4O44
Molecular Weight: 883.09 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: Powder
Source: The herbs of Ampelopsis japonica (Thunb.) Makino
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Download: COA    MSDS    SDF    Manual
Similar structural: Comparison (Web)  (SDF)
Guestbook:
Contact Us
Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC
How to Order
Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com
Delivery time
Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal
Citing Use of our Products
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
Size /Price /Stock 10 mM * 1 mL in DMSO / Inquiry
Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
Our products had been exported to the following research institutions and universities, And still growing.
  • Universiti Putra Malaysia(UPM) (Malaysia)
  • Tokyo Woman's Christian University (Japan)
  • Leibniz Institute of Plant Bioc... (Germany)
  • Universidade Federal de Goias (... (Brazil)
  • Macau University of Science and... (China)
  • Georgia Institute of Technology (USA)
  • University of Lodz (Poland)
  • University of Wollongong (Australia)
  • Chinese University of Hong Kong (China)
  • Funda??o Universitária de Dese... (Brazil)
  • University of Limpopo (South Africa)
  • More...
Package
Featured Products
Notoginsenoside Fc

Catalog No: CFN93283
CAS No: 88122-52-5
Price: $198/20mg
Beta-Carotene

Catalog No: CFN98117
CAS No: 7235-40-7
Price: $40/20mg
Lycopsamine

Catalog No: CFN00287
CAS No: 10285-07-1
Price: $ /
Luteolin-3-O-beta-D-glucuronide

Catalog No: CFN93187
CAS No: 53527-42-7
Price: $238/10mg
Methyl rosmarinate

Catalog No: CFN97567
CAS No: 99353-00-1
Price: $268/20mg
Parkeol

Catalog No: CFN92825
CAS No: 514-45-4
Price: $ / mg
Gracillin

Catalog No: CFN98537
CAS No: 19083-00-2
Price: $80/20mg
Tenuifolin

Catalog No: CFN98157
CAS No: 20183-47-5
Price: $100/20mg
trans-Caryophyllene

Catalog No: CFN90502
CAS No: 87-44-5
Price: $30/20mg
Uridine

Catalog No: CFN97000
CAS No: 58-96-8
Price: $30/20mg
Related Screening Libraries
Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries
Biological Activity
Description: Quetiapine fumarate monotherapy (150 mg/day and 300 mg/day) is effective, with safety and tolerability in the treatment of patients with major depressive disorder. Quetiapine fumarate can treat patients with schizophrenia.
Targets: Androgen Receptor | Estrogen receptor | Progestogen receptor
In vivo:
CNS Neurosci Ther. 2013 Oct;19(10):737-44.
Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair.[Pubmed: 23870612 ]

METHODS AND RESULTS:
Quetiapine fumarate is an atypical antipsychotic with reported remyelinating and neuroprotective properties in inflammatory and noninflammatory models of demyelination, including experimental autoimmune encephalomyelitis, and both cuprizone- and global cerebral ischemia-induced demyelination. Preclinical studies suggest that quetiapine may exert these effects by stimulating proliferation and maturation of oligodendrocytes, releasing neurotrophic factors, increasing antioxidant defences, scavenging for free radicals, and inhibiting activated microglia, astrocytes, and T lymphocytes. Additionally, quetiapine may be beneficial for psychiatric and nonpsychiatric symptoms of MS including depression, anxiety, insomnia, and possibly even pain.
CONCLUSIONS:
These data indicate that clinical trials are justified to determine the safety, tolerability, and efficacy of Quetiapine fumarate in MS.
Clin Pharmacokinet. 2014 May;53(5):455-65.
Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia.[Pubmed: 24385309]
The extended-release formulation of quetiapine (quetiapine XR), which was developed to provide more convenient once-daily administration, has been widely studied to characterize its pharmacokinetics in Caucasian populations but has rarely been studied in an Asia population. This study was conducted to evaluate the pharmacokinetics and tolerability of quetiapine XR administered as a single dose (300 mg) and multiple doses (300, 600, and 800 mg) in Han Chinese patients with schizophrenia.
METHODS AND RESULTS:
This was a single-center, open-label, single-dose and multiple-dose randomized study. Among the 55 randomized subjects, a total of 40 female or male patients in 300 mg (n = 13), 600 mg (n = 13), or 800 mg (n = 14) groups completed the study of Quetiapine fumarate XR. The treatment phase consisted of 5 consecutive days and was preceded by a 1- to 2-day titration period for the 600 and 800 mg groups. Pharmacokinetic parameters for both quetiapine and N-desalkyl quetiapine (norquetiapine) were determined. The tolerability evaluation included adverse events (AEs) noted by monitoring, physical examinations, vital signs, and clinical laboratory tests. N-desalkyl quetiapine was formed from quetiapine with an approximate metabolite to parent ratio of 0.5 across the three dose groups. The geometric mean elimination half-life (t ½) of both quetiapine and N-desalkyl quetiapine was consistent for the three dosing groups (approximately 7 h for quetiapine and approximately 18 h for N-desalkyl quetiapine). The geometric mean maximum plasma concentrations (C max) at steady state (C max,ss) of quetiapine for the three groups were 467, 740, and 1,126 ng/mL, respectively, and for N-desalkyl quetiapine were 138, 262, and 426 ng/mL, respectively. The values for the geometric mean area under the plasma concentration-time curve over a dosing interval at the steady-state (AUCss) of quetiapine were 5,094, 7,685, and 13,237 ng·h/mL, respectively, and for N-desalkyl quetiapine were 2,284, 4,341, and 7,216 ng·h/mL, respectively. The apparent oral clearance (CL/F) of quetiapine at steady state appeared to be comparable across the three dose groups. The pharmacokinetics of quetiapine XR were dose-proportional across the dosage range employed. The most common AE was somnolence, but all of the reported AEs were mild. There were no serious AEs or other significant AEs.
CONCLUSIONS:
Quetiapine fumarate XR has a dose-proportional pharmacokinetic profile at doses ranging from 300 to 800 mg once daily, and a slower time to reach C max and steady state after 3 days of sequential dosing. Therefore, it offers a simple and rapid dose-escalation option and more convenient once-daily administration. The three dosages of Quetiapine fumarate XR were generally well-tolerated in this pharmacokinetic study of Han Chinese patients with schizophrenia.
J Clin Psychiatry. 2009 Apr;70(4):526-39.
Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.[Pubmed: 19358790]
To evaluate the efficacy and tolerability of once-daily extended release Quetiapine fumarate (quetiapine XR) as monotherapy treatment for major depressive disorder (MDD).
METHODS AND RESULTS:
This 8-week (6-week active-treatment, randomized phase; 2-week posttreatment drug-discontinuation/tapering phase), multicenter, double-blind, randomized, parallel-group, placebo- and active-controlled, phase 3 study was conducted between April 2006 and May 2007. In total, 612 patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)-defined MDD were randomly assigned to quetiapine XR 150 mg/day or 300 mg/day, duloxetine 60 mg/day (active control), or placebo. The primary endpoint was the change from baseline to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score.
CONCLUSIONS:
Quetiapine XR monotherapy (150 mg/day and 300 mg/day) is effective, with safety and tolerability consistent with the known profile of quetiapine XR, in the treatment of patients with MDD, with onset of symptom improvement demonstrated at week 1.
Psychopharmacol Bull. 2008;41(3):11-35.
The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.[Pubmed: 18779774]
This study aimed to demonstrate efficacy of once-daily extended release Quetiapine fumarate (quetiapine XR) versus placebo in patients with acute schizophrenia.
METHODS AND RESULTS:
In this 6-week, randomized, double-blind study (5077IL/0041) patients were randomized to receive quetiapine XR (300, 600, or 800 mg/day), Quetiapine fumarate immediate release (quetiapine IR) [300 or 600 mg/day], or placebo. Primary endpoint was change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Day 42. Secondary variables included PANSS response rate at Day 42 (>/=30% decrease in PANSS total score from baseline) and Clinical Global Impressions Severity (CGI-S) and Improvement (CGI-I) ratings. Safety assessments included adverse event (AE) reporting and laboratory measures. Of 532 patients randomized, 222 (41.7%) completed the study. Improvements in PANSS total scores from baseline to Day 42 across treatment groups were: quetiapine XR 300 mg/day -5.01, 600 mg/day -13.01 and 800 mg/day -11.17, quetiapine IR 300 mg/day -9.42 and 600 mg/day -6.97, and placebo -5.19; the difference in change was statistically significant only for quetiapine XR 600 mg/day (p = 0.033). There were no statistically significant differences between active treatment groups and placebo for PANSS response rates. Several post hoc analyses were conducted to explain the study efficacy outcome but these were inconclusive. Quetiapine XR was generally well tolerated with the majority of AEs being mild or moderate in intensity and no unexpected AEs.
CONCLUSIONS:
Superior efficacy of quetiapine XR versus placebo in patients with schizophrenia was demonstrated for quetiapine XR 600 mg/day. The safety and tolerability profile of quetiapine XR was similar to that of quetiapine IR.
Quetiapine fumarate Description
Source: The herbs of Ampelopsis japonica (Thunb.) Makino
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
ChemFaces New Products and Compounds
Jacquilenin

Catalog No: CFN95434
CAS No: 7726-34-3
Price: $318/5mg
10-O-trans-p-coumaroylscandoside

Catalog No: CFN95391
CAS No: 870785-25-4
Price: $318/10mg
Cuneataside C

Catalog No: CFN95368
CAS No: 871720-16-0
Price: $318/10mg
Patulitrin

Catalog No: CFN95153
CAS No: 19833-25-1
Price: $318/10mg
Glaucoside C

Catalog No: CFN95300
CAS No: 81474-89-7
Price: $318/5mg
3'-Hydroxymirificin

Catalog No: CFN95102
CAS No: 168035-02-7
Price: $338/5mg
Suchilactone

Catalog No: CFN95010
CAS No: 50816-74-5
Price: $338/5mg
Ephedrannin D1

Catalog No: CFN95547
CAS No: 1592431-55-4
Price: $318/5mg
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.1324 mL 5.6619 mL 11.3239 mL 22.6477 mL 28.3097 mL
5 mM 0.2265 mL 1.1324 mL 2.2648 mL 4.5295 mL 5.6619 mL
10 mM 0.1132 mL 0.5662 mL 1.1324 mL 2.2648 mL 2.831 mL
50 mM 0.0226 mL 0.1132 mL 0.2265 mL 0.453 mL 0.5662 mL
100 mM 0.0113 mL 0.0566 mL 0.1132 mL 0.2265 mL 0.2831 mL
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
Notoginsenoside Fc

Catalog No: CFN93283
CAS No: 88122-52-5
Price: $198/20mg
Beta-Carotene

Catalog No: CFN98117
CAS No: 7235-40-7
Price: $40/20mg
Lycopsamine

Catalog No: CFN00287
CAS No: 10285-07-1
Price: $ /
Luteolin-3-O-beta-D-glucuronide

Catalog No: CFN93187
CAS No: 53527-42-7
Price: $238/10mg
Methyl rosmarinate

Catalog No: CFN97567
CAS No: 99353-00-1
Price: $268/20mg
Parkeol

Catalog No: CFN92825
CAS No: 514-45-4
Price: $ / mg
Gracillin

Catalog No: CFN98537
CAS No: 19083-00-2
Price: $80/20mg
Tenuifolin

Catalog No: CFN98157
CAS No: 20183-47-5
Price: $100/20mg
trans-Caryophyllene

Catalog No: CFN90502
CAS No: 87-44-5
Price: $30/20mg
Uridine

Catalog No: CFN97000
CAS No: 58-96-8
Price: $30/20mg
Tags: buy Quetiapine fumarate | Quetiapine fumarate supplier | purchase Quetiapine fumarate | Quetiapine fumarate cost | Quetiapine fumarate manufacturer | order Quetiapine fumarate | Quetiapine fumarate distributor